WO2011123044A1 - Method to detect tissue degradation leading to inflammation - Google Patents

Method to detect tissue degradation leading to inflammation Download PDF

Info

Publication number
WO2011123044A1
WO2011123044A1 PCT/SE2011/050369 SE2011050369W WO2011123044A1 WO 2011123044 A1 WO2011123044 A1 WO 2011123044A1 SE 2011050369 W SE2011050369 W SE 2011050369W WO 2011123044 A1 WO2011123044 A1 WO 2011123044A1
Authority
WO
WIPO (PCT)
Prior art keywords
comp
sample
complement
complex
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2011/050369
Other languages
English (en)
French (fr)
Inventor
Anna Blom
Kaisa Happonen
Dick HEINEGÅRD
Tore Saxne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anamar AB
Original Assignee
Anamar AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anamar AB filed Critical Anamar AB
Priority to AU2011233753A priority Critical patent/AU2011233753A1/en
Priority to EP11763156.4A priority patent/EP2553465A4/en
Priority to US13/636,145 priority patent/US20130084584A1/en
Priority to JP2013502539A priority patent/JP2013524213A/ja
Publication of WO2011123044A1 publication Critical patent/WO2011123044A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Definitions

  • tissue degradation processes for the purpose of diagnosis, disease monitoring, treatment etc. can be performed by numerous methods.
  • One way to determine degradation processes in connective tissue diseases, such as arthritic conditions; artheriosclerosis, degenerative joint conditions etc. is the detection of the presence of degradation products of the connective tissue components. This allows direct detection of the degradation process, compared to indirect methods as e.g. measuring increased amounts of leukocytes, which have been employed in the diagnosis of inflammatory processes such as arthritic conditions.
  • Another parameter is the late in the process observed tissue loss detected by imaging methods such as X-ray or MRI.
  • WO2004031240 describes a method to inhibit inflammatory reactions in vivo, more specifically the activation of the complement system.
  • the invention consists of the
  • WO2008154251 the invention concerns specific antibodies to C3b and the prevention and treatment of complement-associated disorders using such antibodies.
  • a primary object of the present invention is to provide an assay that can be used to measure and to monitor the success of ongoing treatment regimes, i.e. the signal in the COMP-C3b assay follows disease activity in the patient.
  • Another object of the present invention is to provide an improved assay for identifying patients with RA.
  • An embodiment of the invention is an assay, as in the method of the invention, where the sample is used for measuring the complement activation in suspected RA and OA
  • An embodiment of the invention is an assay, as in the method of the invention, for monitoring the disease progression in patients with diseases with inflammatory components and affecting connective tissues such as RA and OA, systemic sclerosis, tendinitis and cardiovascular disease including atherosclerosis.
  • FIG 1 shows the levels of serum COMP-C3b complexes in various disease groups. DETAILED DESCRIPTION OF THE INVENTION
  • the invention is aimed to be used to detect inflammation in general in a patient.
  • a first component providing an antibody for example a monoclonal antibody or an other ligand, directed against human COMP, either in solution or bound to a solid phase carrier, such as a well in a plate ,
  • the invention will define high risk patients with a more intense disease progression.
  • Cartilage matrix proteins An acidic oligomeric protein (COMP) detected only in cartilage. J Biol Chem 1992. 267: 6132-6136.
  • COMP acidic oligomeric protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PCT/SE2011/050369 2010-03-31 2011-03-30 Method to detect tissue degradation leading to inflammation Ceased WO2011123044A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2011233753A AU2011233753A1 (en) 2010-03-31 2011-03-30 Method to detect tissue degradation leading to inflammation
EP11763156.4A EP2553465A4 (en) 2010-03-31 2011-03-30 METHOD FOR DETECTING INFLAMMATION TISSUE DEGRADATION
US13/636,145 US20130084584A1 (en) 2010-03-31 2011-03-30 Method to detect tissue degradation leading to inflammation
JP2013502539A JP2013524213A (ja) 2010-03-31 2011-03-30 炎症をもたらす組織分解を検出する方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1050310 2010-03-31
SE1050310-0 2010-03-31

Publications (1)

Publication Number Publication Date
WO2011123044A1 true WO2011123044A1 (en) 2011-10-06

Family

ID=44712493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2011/050369 Ceased WO2011123044A1 (en) 2010-03-31 2011-03-30 Method to detect tissue degradation leading to inflammation

Country Status (5)

Country Link
US (1) US20130084584A1 (https=)
EP (1) EP2553465A4 (https=)
JP (1) JP2013524213A (https=)
AU (1) AU2011233753A1 (https=)
WO (1) WO2011123044A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3771468A1 (en) * 2019-07-31 2021-02-03 Universitätsklinikum Hamburg-Eppendorf C3/c5 convertase assays

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038876A1 (en) * 1999-11-22 2001-05-31 Anamar Medical Ab Sandwich immunoassay and monoclonal antibodies for comp, cartillage oligomeric matrix protein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) * 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4642284A (en) * 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation
SE452065B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
IL84160A0 (en) * 1986-10-16 1988-03-31 Vasocor Method and kit for immune complex assay
KR20000064637A (ko) * 1996-03-19 2000-11-06 에프.지.엠. 헤르만스 비(b)형 간염의 감염 결과를 예측하는 방법
CA2502926A1 (en) * 2002-11-08 2004-05-27 Linda J. Sandell Uncoupled collagen synthesis and degradation assays
ES2360804T3 (es) * 2004-05-24 2011-06-09 Anamar Ab Método para determinar un proceso de degradación tisular mediante la detección de neoepítopos de comp.
BRPI0812767A2 (pt) * 2007-06-07 2014-12-02 Genentech Inc Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento
CA2690568A1 (en) * 2007-06-20 2008-12-24 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
EP3112379A1 (en) * 2008-03-21 2017-01-04 Universiteit Hasselt Biomarkers for rheumatoid arthritis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038876A1 (en) * 1999-11-22 2001-05-31 Anamar Medical Ab Sandwich immunoassay and monoclonal antibodies for comp, cartillage oligomeric matrix protein

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HAPPONEN K. E. ET AL.: "Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis", ARTHRITIS & RHEUMATISM, vol. 62, no. 12, December 2010 (2010-12-01), pages 3574 - 3583, XP055077607 *
HAPPONEN K.E. ET AL.: "Cartilage oligomeric matrix protein (COMP) has a dual role in complement regulation", MOLECULAR IMMUNOLOGY, vol. 46, no. 14, 2009, pages 2829, XP026438412
SAXNE T. ET AL.: "Cartilage oligomeric matrix protein: A novel marker of cartialge turnover detectable in synovial fluid and blood", BRITISH JOURNAL OF RHEUMATOLOGY, vol. 31, no. 9, 1992, pages 583 - 591, XP008164647 *
See also references of EP2553465A4 *
SJOBERG A.P. ET AL: "Complement activation and inhibition: a delicate balance", TRENDS IN IMMUNOLOGY, vol. 30, no. 2, 2009, pages 83 - 90, XP025959598 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3771468A1 (en) * 2019-07-31 2021-02-03 Universitätsklinikum Hamburg-Eppendorf C3/c5 convertase assays
WO2021019081A1 (en) * 2019-07-31 2021-02-04 Universitätsklinikum Hamburg-Eppendorf C3/c5 convertase assays

Also Published As

Publication number Publication date
JP2013524213A (ja) 2013-06-17
EP2553465A1 (en) 2013-02-06
EP2553465A4 (en) 2013-10-23
US20130084584A1 (en) 2013-04-04
AU2011233753A1 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
JP7441662B2 (ja) ｐＫａｌ関連疾病の評価、アッセイおよび治療
Dambinova et al. Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke
Rau et al. Laboratory markers of severe acute pancreatitis
TR201815856T4 (tr) Bradikinin-aracılı rahatsızlıkların değerlendirilmesi ve tedavisi.
JP2014525593A (ja) 心臓血管リスクを予測するための診断分析
JP7317379B2 (ja) 潰瘍性大腸炎及び原発性硬化性胆管炎の検査方法
JP2011521216A (ja) 関節リウマチの診断のための方法およびキット
US20230258660A1 (en) A method for distinguishing healthy individuals from individuals having infectious or inflammatory conditions
JP7168688B2 (ja) 補体Ｃ４ｄアッセイ
US20140186293A1 (en) Immunoglobulin-bound extracellular vesicles and uses thereof
US20130084584A1 (en) Method to detect tissue degradation leading to inflammation
CA3129624A1 (en) Compositions and methods for diagnosing and assessing rheumatoid arthritis
CN107484423A (zh) 通过测量抗ccp和抗pik3cd来评估类风湿性关节炎的方法
US20040241763A1 (en) Method for diagnosing multiple sclerosis
JPWO2014148429A1 (ja) 非特異的間質性肺炎の診断のためのバイオマーカー
JP5651890B2 (ja) 再灌流療法の治療効果を判定するキット
CN121713065A (zh) 使用无细胞核小体水平的诊断方法
JP2020046412A (ja) ＩｇＧ４関連疾患の検査方法
JP2023525219A (ja) タンパク質－アルギニンデイミナーゼ１（ｐａｄ１）自己抗原を使用する関節リウマチの診断及び評価のための組成物及び方法
JP2013064616A (ja) 高度動脈硬化を発症している可能性を検出する方法およびその利用
Fat-Yiu Serum high-sensitivity C-reactive protein concentration of Chinese chronic-renal-failure patients with atherosclerotic vascular disease or cardiac valve calcification
EP3056903A1 (en) Method of assessing rheumatoid arthritis by measuring anti-CCP and anti-Casp8
EP3056904A1 (en) Method of assessing rheumatoid arthritis by measuring anti-CCP and anti-MCM3

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11763156

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011233753

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2011763156

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011763156

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011233753

Country of ref document: AU

Date of ref document: 20110330

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013502539

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13636145

Country of ref document: US